The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Open accessAbstract
Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of which has reached phase 3. These bsAbs show great variability in design and mechanism of action. The various designs are often linked to the mechanisms of actions. The majority of bsAbs engage immune cells to destroy tumor cells. However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways. This review provides insight into the choice of construct for bsAbs, summarizes the clinical development of bsAbs in oncology and identifies subsequent challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · cited 7×
“Blinatumomab, targeting CD19 and CD3, was approved by the FDA in December 2014 and by the EMA in December 2015 for the treatment of Philadelphia chromosome negative B cell acute lymphoblastic leukemia (ALL) (Przepiorka et al., 2015).”
BackgroundInfluentialCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“also used to reduce cytokine release syndrome (Lee et al., 2014; Maude et al., 2014).”
MethodNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · cited 1×
“A combination of nivolumab, an anti-PD-1 antibody, with ipilimumab, an anti-CTLA4 antibody, has been approved by the FDA and EMA for metastatic melanoma (Postow et al., 2015).”
BackgroundFcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,666
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 710
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O. O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknaviciene, B., Razbadauskas, A., Gore, M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25423 · Cited by 549
Antibody Therapeutics in Cancer
Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 543
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
Birch, J. R., & Racher, A. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.12.006 · Cited by 471
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Vallera, D. A., Felices, M., McElmurry, R., McCullar, V., Zhou, X., Schmohl, J. U., Zhang, B., Lenvik, A. J., Panoskaltsis-Mortari, A., Verneris, M. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2710 · Cited by 391
Przepiorka, D., Ko, C.-W., Deisseroth, A., Yancey, C. L., Candau-Chacon, R., Chiu, H.-J., Gehrke, B. J., Gomez-Broughton, C., Kane, R. C., Kirshner, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0612 · Cited by 373
Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351 · cited 1×
“Bispecific T cell Engager (BiTE) Consists of two scFvs, VLA VHA and VHB VLB on one peptide chain (Mack et al., 1995).”
BackgroundDreier, T., Lorenczewski, G., Brandl, C., Hoffmann, P., Syring, U., Hanakam, F., Kufer, P., Riethmuller, G., Bargou, R., & Baeuerle, P. A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10557 · Cited by 348
Bacac, M., Fauti, T., Sam, J., Colombetti, S., Weinzierl, T., Ouaret, D., Bodmer, W., Lehmann, S., Hofer, T., Hosse, R. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1696 · Cited by 345
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 339
Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Monoclonal TCR-redirected tumor cell killing
Liddy, N., Bossi, G., Adams, K. J., Lissina, A., Mahon, T. M., Hassan, N. J., Gavarret, J., Bianchi, F. C., Pumphrey, N. J., Ladell, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2764 · Cited by 324
MacDiarmid, J. A., Mugridge, N. B., Weiss, J. C., Phillips, L., Burn, A. L., Paulin, R. P., Haasdyk, J. E., Dickson, K.-A., Brahmbhatt, V. N., Pattison, S. T., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.012 · Cited by 307
Human Immune Respone to Monoclonal Antibodies
Khazaeli, M. B., Conry, R. M., & LoBuglio, A. F. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199401000-00006 · Cited by 301
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
Li, J., Stagg, N. J., Johnston, J., Harris, M. J., Menzies, S. A., DiCara, D., Clark, V., Hristopoulos, M., Cook, R., Slaga, D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.001 · Cited by 296
Irani, V., Guy, A. J., Andrew, D., Beeson, J. G., Ramsland, P. A., & Richards, J. S. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.03.255 · Cited by 288
Bispecific antibodies and their applications
Fan, G., Wang, Z., Hao, M., & Li, J. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0227-0 · Cited by 288
Moores, S. L., Chiu, M. L., Bushey, B. S., Chevalier, K., Luistro, L., Dorn, K., Brezski, R. J., Haytko, P., Kelly, T., Wu, S.-J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2833 · Cited by 286
Seimetz, D., Lindhofer, H., & Bokemeyer, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.001 · Cited by 284
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
Ring, N. G., Herndler-Brandstetter, D., Weiskopf, K., Shan, L., Volkmer, J.-P., George, B. M., Lietzenmayer, M., McKenna, K. M., Naik, T. J., McCarty, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710877114 · Cited by 283
McDonagh, C. F., Huhalov, A., Harms, B. D., Adams, S., Paragas, V., Oyama, S., Zhang, B., Luus, L., Overland, R., Nguyen, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0820 · Cited by 278
Duell, J., Dittrich, M., Bedke, T., Mueller, T., Eisele, F., Rosenwald, A., Rasche, L., Hartmann, E., Dandekar, T., Einsele, H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.41 · Cited by 278
Applications of single-chain variable fragment antibodies in therapeutics and diagnostics
Weisser, N. E., & Hall, J. C. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.04.004 · Cited by 261
Moore, P. A., Zhang, W., Rainey, G. J., Burke, S., Li, H., Huang, L., Gorlatov, S., Veri, M. C., Aggarwal, S., Yang, Y., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306449 · Cited by 260
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Lichtenegger, F. S., Köhnke, T., Vick, B., Jeremias, I., Metzeler, K. H., Altmann, T., et al. (2016) · Leukemia · doi:10.1038/leu.2015.214 · Cited by 253
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Bacac, M., Colombetti, S., Herter, S., Sam, J., Perro, M., Chen, S., Bianchi, R., Richard, M., Schoenle, A., Nicolini, V., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0455 · Cited by 249
Merchant, M., Ma, X., Maun, H. R., Zheng, Z., Peng, J., Romero, M., Huang, A., Yang, N.-Y., Nishimura, M., Greve, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302725110 · Cited by 236
Chatal, J.-F., Campion, L., Kraeber-Bodéré, F., Bardet, S., Vuillez, J.-P., Charbonnel, B., Rohmer, V., Chang, C.-H., Sharkey, R. M., Goldenberg, D. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4917 · Cited by 232
Pretargeted Imaging and Therapy
Altai, M., Membreno, R., Cook, B. E., Максимилианович, Т. В., & Zeglis, B. M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.189944 · Cited by 231
Müller, D., Karle, A., Meißburger, B., Höfig, I., Stork, R., & Kontermann, R. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700820200 · Cited by 222
Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman, O. C., van Schaijk, F. G., Oyen, W. J. G., et al. (2003) · PubMed · Cited by 216
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., McBride, W. J., Sharkey, R. M., & Chang, C.-H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600982103 · Cited by 209 · cited 1×
“XmAb14045, XmAb13676, XmAb18087, XmAb20717, AMG424, GBR1302, GBR1342 TF Three Fab fragments are linked by disulfide bridges (Rossi et al., 2006).”
BackgroundAn anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
Ishiguro, T., Sano, Y., Komatsu, S.-I., Kamata-Sakurai, M., Kaneko, A., Kinoshita, Y., Shiraiwa, H., Azuma, Y., Tsunenari, T., Kayukawa, Y., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4291 · Cited by 207
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.-W., Matys, E. R., & Little, M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3156 · Cited by 202
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Half-life extended biotherapeutics
Kontermann, R. E. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1165661 · Cited by 191
Huang, S., Li, C., Armstrong, E. A., Peet, C. R., Saker, J., Amler, L. C., Sliwkowski, M. X., & Harari, P. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1611 · Cited by 188
Brischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S. A., Kiener, P., Kufer, P., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156750c · Cited by 187
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
Klein, C., Schaefer, W., & Regula, J. T. (2016) · mAbs · doi:10.1080/19420862.2016.1197457 · Cited by 185
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Haas, C., Krinner, E., Brischwein, K., Hoffmann, P., Lutterbüse, R., Schlereth, B., Kufer, P., & Baeuerle, P. A. (2009) · Immunobiology · doi:10.1016/j.imbio.2008.11.014 · Cited by 178
Kebenko, M., Goebeler, M.-E., Wolf, M., Hasenburg, A., Seggewiss-Bernhardt, R., Ritter, B., Rautenberg, B., Atanackovic, D., Kratzer, A., Rottman, J. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1450710 · Cited by 177
Practical Theoretic Guidance for the Design of Tumor-Targeting Agents
Wittrup, K. D., Thurber, G. M., Schmidt, M. M., & Rhoden, J. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-396962-0.00010-0 · Cited by 171
Tabernero, J., Melero, I., Ros, W., Argiles, G., Marabelle, A., Rodriguez-Ruiz, M. E., Albanell, J., Calvo, E., Moreno, V., Cleary, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3002 · Cited by 170
Smith, E. J., Olson, K., Haber, L. J., Varghese, B., Duramad, P., Tustian, A. D., Oyejide, A., Kirshner, J. R., Canova, L., Menon, J., et al. (2015) · Scientific Reports · doi:10.1038/srep17943 · Cited by 167
Assi, R., Kantarjian, H., Short, N. J., Daver, N., Takahashi, K., Garcia-Manero, G., DiNardo, C., Burger, J., Cortes, J., Jain, N., et al. (2017) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2017.08.101 · Cited by 163
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Wu, Z., & Cheung, N. V. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.005 · Cited by 163
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1
Dao, T., Pankov, D., Scott, A., Korontsvit, T., Zakhaleva, V., Xu, Y., Xiang, J., Yan, S., de Morais Guerreiro, M. D., Veomett, N., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3349 · Cited by 162
Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
Junttila, T. T., Li, J., Johnston, J., Hristopoulos, M. L., Clark, R. A., Ellerman, D. A., Wang, B.-E., Li, Y., Mathieu, M. A., Li, G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3622-t · Cited by 161
Recent advances of bispecific antibodies in solid tumors
Yu, S., Li, A., Liu, Q., Yuan, X., Xu, H., Jiao, D., Pestell, R. G., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0522-z · Cited by 158
An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Leong, S. R., Sukumaran, S., Hristopoulos, M. L., Tótpál, K., Stainton, S. L., Lu, E., Wong, A., Tam, L., Newman, R., Vuillemenot, B. R., et al. (2016) · Blood · doi:10.1182/blood-2016-08-735365 · Cited by 156
Mandikian, D., Takahashi, N., Lo, A. A., Li, J., Eastham-Anderson, J., Slaga, D., Ho, J., Hristopoulos, M., Clark, R., Totpal, K., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0657 · Cited by 155
Doussal, J. M. L., Martin, M., Gautherot, E., DELAAGE, M. A., & Barbet, J. (1989) · PubMed · Cited by 153
Structural and functional characterization of the trifunctional antibody catumaxomab
Chelius, D., Ruf, P., Gruber, P., Plöscher, M., Liedtke, R., Gansberger, E., Heß, J., Wasiliu, M., & Lindhofer, H. (2010) · mAbs · doi:10.4161/mabs.2.3.11791 · Cited by 152
Engineering antibodies for clinical applications
Jain, M., Kamal, N., & Batra, S. K. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.05.001 · Cited by 151
Dheilly, E., Moine, V., Broyer, L., Salgado-Pires, S., Johnson, Z., Papaioannou, A., Cons, L., Calloud, S., Majocchi, S., Nelson, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.006 · Cited by 151
Piccione, E. C., Juárez, S., Liu, J., Tseng, S., Ryan, C. E., Narayanan, C., Wang, L., Weiskopf, K., & Majeti, R. (2015) · mAbs · doi:10.1080/19420862.2015.1062192 · Cited by 148
Brünker, P., Wartha, K., Friess, T., Grau-Richards, S., Waldhauer, I., Ferrara, C., Weiser, B., Majety, M., Runza, V., Niu, H., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0647 · Cited by 145
Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
de Goeij, B. E. C. G., Vink, T., ten Napel, H., Breij, E. C. W., Satijn, D. P. E., Wubbolts, R., Miao, D., & Parren, P. W. H. I. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0364 · Cited by 139
Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing
Ross, S. L., Sherman, M., McElroy, P. L., Lofgren, J. A., Moody, G. E., Baeuerle, P. A., Coxon, A., & Arvedson, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183390 · Cited by 137
OKT3 first-dose reaction: Association with T cell subsets and cytokine release
Gaston, R. S., Deierhoi, M. H., Patterson, T., Prasthofer, E., Julian, B. A., Barber, W. H., Laskow, D. A., Diethelm, A. G., & Curtis, J. J. (1991) · Kidney International · doi:10.1038/ki.1991.18 · Cited by 134
Portell, C. A., Wenzell, & Advani, A. S. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s42689 · Cited by 125
Whittle, J. R., Lickliter, J. D., Gan, H. K., Scott, A. M., Simes, J. R., Solomon, B., MacDiarmid, J. A., Brahmbhatt, H. N., & Rosenthal, M. A. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.06.005 · Cited by 117
Pretargeted Molecular Imaging and Radioimmunotherapy
Goldenberg, D. M., Chang, C., Rossi, E. A., McBride, W. J., & Sharkey, R. M. (2012) · Theranostics · doi:10.7150/thno.3582 · Cited by 115
Fitzgerald, J. B., Johnson, B. W., Baum, J., Adams, S., Iadevaia, S., Tang, J., Rimkunas, V. M., Xu, L., Kohli, N., Rennard, R., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0255 · Cited by 112
Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Lum, L. G., Thakur, A. B., Al-Kadhimi, Z. S., Colvin, G. A., Cummings, F. J., Legare, R. D., Dizon, D. S., KOUTTAB, N. M., Maizel, A., Colaiace, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2280 · Cited by 109
Immunogenicity and other problems associated with the use of biopharmaceuticals
Tovey, M. G., & Lallemand, C. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611406318 · Cited by 108
The use of combinations of monoclonal antibodies in clinical oncology
Henricks, L. M., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.10.008 · Cited by 106
Fayette, J., Wirth, L. J., Oprean, C. M., Udrea, A. A., Jimeno, A., Rischin, D., Nutting, C. M., Harari, P. M., Csőszi, T., Cernea, D. M., et al. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00232 · Cited by 104
Root, A. R., Cao, W., Li, B., LaPan, P., Meade, C., Sanford, J. D., Jin, M., O’Sullivan, C., Cummins, E., Lambert, M. A., et al. (2016) · Antibodies · doi:10.3390/antib5010006 · Cited by 103
Osada, T., Patel, S. P., Hammond, S. A., Osada, K., Morse, M. A., & Lyerly, H. K. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1671-y · Cited by 101
Schoffelen, R., Boerman, O. C., Goldenberg, D. M., Sharkey, R. M., van Herpen, C. M. L., Franssen, G. M., McBride, W. J., Chang, C.-H., Rossi, E. A., van der Graaf, W. T. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.376 · Cited by 98
Pretargeting with the Affinity Enhancement System for Radioimmunotherapy
Barbet, J., Kraeber‐Bodéré, F., Vuillez, J.-P., Gautherot, E., Rouvier, É., & Chatal, J. (1999) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1999.14.153 · Cited by 96
Bispecific antibody platforms for cancer immunotherapy
Lameris, R., de Bruin, R. C. G., Schneiders, F. L., Henegouwen, P. M. P. V. B. E., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.08.003 · Cited by 90
ImmTACs for targeted cancer therapy: Why, what, how, and which
Oates, J., Hassan, N. J., & Jakobsen, B. K. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.024 · Cited by 90
Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
Weidle, U. H., Kontermann, R. E., & Brinkmann, U. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.004 · Cited by 89
Chang, C., Wang, Y., Li, R., Rossi, D. L., Liu, D., Rossi, E. A., Cardillo, T. M., & Goldenberg, D. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3431 · Cited by 89
Fury, M. G., Lipton, A., Smith, K. M., Winston, C. B., & Pfister, D. G. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0357-5 · Cited by 87
Vallera, D. A., Chen, H., Sicheneder, A. R., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.02.006 · Cited by 87
Solomon, B., Desai, J., Rosenthal, M. A., McArthur, G. A., Pattison, S. T., Pattison, S. L., MacDiarmid, J. A., Brahmbhatt, H. N., & Scott, A. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144559 · Cited by 87
Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy.
Knight, J. C., & Cornelissen, B. T. (2014) · Oxford University Research Archive (ORA) (University of Oxford) · Cited by 86
Moore, P. A., Shah, K., Yang, Y., Alderson, R. F., Roberts, P., Long, V., Liu, D., Li, J. C., Burke, S., Ciccarone, V. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1086 · Cited by 79
Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry
van de Watering, F. C. J., Rijpkema, M., Robillard, M. S., Oyen, W. J. G., & Boerman, O. C. (2014) · Frontiers in Medicine · doi:10.3389/fmed.2014.00044 · Cited by 76
Bispecific digoxigenin-binding antibodies for targeted payload delivery
Metz, S., Haas, A. K., Daub, K., Croasdale, R., Stracke, J. O., Lau, W., Georges, G. J., Josel, H., Dziadek, S., Hopfner, K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018565108 · Cited by 73
Hernández‐Hoyos, G., Sewell, T., Bader, R., Bannink, J. E., Chenault, R. A., Daugherty, M., Dasovich, M., Fang, H., Gottschalk, R. J., Kumer, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0242 · Cited by 73
Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule
Jakob, C. G., Edalji, R. P., Judge, R. A., DiGiammarino, E. L., Li, Y., Gu, J., & Ghayur, T. (2013) · mAbs · doi:10.4161/mabs.23977 · Cited by 72
Bodet‐Milin, C., Faivre-Chauvet, A., Carlier, T., Rauscher, A., Bourgeois, M., Cerato, E., Rohmer, V., Couturier, O., Drui, D., Goldenberg, D. M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.172221 · Cited by 72
Liu, L., Lam, C. K., Long, V., Widjaja, L., Yang, Y., Li, H., Jin, L. X., Burke, S., Gorlatov, S. N., Brown, J. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0666 · Cited by 72
Bachanová, V., Frankel, A. E., Cao, Q., Lewis, D., Grzywacz, B. J., Verneris, M. R., Üstün, C., Lazaryan, A., McClune, B. L., Warlick, E. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2877 · Cited by 67
Green, D. J., O’Steen, S., Lin, Y., Comstock, M., Kenoyer, A. L., Hamlin, D. K., Wilbur, D. S., Fisher, D. R., Nartea, M. E., Hylarides, M. D., et al. (2017) · Blood · doi:10.1182/blood-2017-09-807610 · Cited by 65
Novel radiolabeled antibody conjugates
Goldenberg, D. M., & Sharkey, R. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210373 · Cited by 64
Arndt, C., Feldmann, A., Bonin, M. V., Cartellieri, M., Ewen, E.-M., Koristka, S., Michalk, I., Stamova, S., Berndt, N., Gocht, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.243 · Cited by 64
Hill, A. G., Findlay, M. P. N., Burge, M., Jackson, C., Alfonso, P., Samuel, L. M., Ganju, V., Karthaus, M., Amatu, A., Jeffery, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0646 · Cited by 63
Grosse‐Hovest, L., Hartlapp, I., Marwan, W., Brem, G., Rammensee, H., & Jung, G. (2003) · European Journal of Immunology · doi:10.1002/eji.200323322 · Cited by 62
The antibody–drug conjugate target landscape across a broad range of tumour types
Moek, K. L., de Groot, D. J. A., de Vries, E. G. E., & Fehrmann, R. S. N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx541 · Cited by 60
Patnaik, A., Gordon, M. S., Tsai, F. Y.-C., Papadopoulos, K. P., Rasco, D. W., Beeram, S., Fu, S., Jankú, F., Hynes, S. M., Gundala, S. R., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3623-7 · Cited by 60
Moek, K. L., Waaijer, S. J. H., Kok, I. C., Suurs, F. V., Brouwers, A. H., van Oordt, C. W. M. D. H., Wind, T. T., Gietema, J. A., Schröder, C. P., Mahesh, S. V. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2918 · Cited by 59
Self-citationTHE MECHANISM OF ANTI-CD3 MONOCLONAL ANTIBODIES: MEDIATION OF CYTOLYSIS BY INTER-T CELL BRIDGING
Wong, J. T., Eylath, A., Ghobrial, I. I., & Colvin, R. B. (1990) · Transplantation · doi:10.1097/00007890-199010000-00030 · Cited by 53
Li, J., Ybarra, R., Mak, J., Hérault, A., de Almeida, P. E., Arrazate, A., Ziai, J. M., Tótpál, K., Junttila, M. R., Walsh, K. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1139 · Cited by 46
Amann, M., Friedrich, M., Lutterbuese, P., Vieser, E., Lorenczewski, G., Petersen, L., Brischwein, K., Kufer, P., Kischel, R., Baeuerle, P. A., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0529-y · Cited by 41
Bispecific antibody: a tool for diagnosis and treatment of disease
Songsivilai, S., & Lachmann, P. J. (1990) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb08089.x · Cited by 39
Otz, T., Große-Hovest, L., Hofmann, M., Rammensee, H.-G., & Jung, G. (2009) · Leukemia · doi:10.1038/leu.2008.271 · Cited by 38
Lum, L. G., Thakur, A. B., Liu, Q., Deol, A., Al-Kadhimi, Z. S., Ayash, L. J., Abidi, M. H., Pray, C., Tomaszewski, E. N., Steele, P. A., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.03.010 · Cited by 38
Richards, D., Braiteh, F. S., García, A. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.651 · Cited by 38
HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy
Ma, J., Han, H., Liu, D., li, W., Feng, H., Xue, X., Wu, X., Niu, G., Zhang, G., Zhao, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073261 · Cited by 36
Kroesen, B., Nieken, J., Sleijfer, D. T., Molema, G., de Vries, E. G. E., Groen, H. J. M., Helfrich, W., THE, T. H., Mulder, N. H., & de Leij, L. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050433 · Cited by 35
Schultink, A. H. M. D. V., Doornbos, R. P., Bakker, A. B. H., Bol, K., Throsby, M., Geuijen, C. A. W., Maussang, D., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0593-x · Cited by 34
Waaijer, S. J. H., Warnders, F. J., Stienen, S., Friedrich, M., Sternjak, A., Cheung, H. K., van Scheltinga, A. G. T. T., Schröder, C. P., de Vries, E. G. E., & Hooge, M. N. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0786 · Cited by 34
Schuster, F. R., Stanglmaier, M., Woessmann, W., Winkler, B., Siepermann, M., Meisel, R., Schlegel, P. G., Hess, J., Lindhofer, H., Borkhardt, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13242 · Cited by 33
Rapid optimization and prototyping for therapeutic antibody-like molecules
Xu, L., Kohli, N., Rennard, R., Jiao, Y., Razlog, M., Zhang, K., Baum, J., Johnson, B. W., Tang, J., Schoeberl, B., et al. (2013) · mAbs · doi:10.4161/mabs.23363 · Cited by 29
Argilés, G., Saro, J., Segal, N. H., Melero, I., Ros, W., Marabelle, A., Rodríguez, M. E., Albanell, J., Calvo, E., Moreno, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx302.003 · Cited by 29
Activated T cells armed with bispecific antibodies kill tumor targets
Bhutani, D., & Lum, L. G. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000176 · Cited by 27
Segal, N. H., Saro, J., Melero, I., Ros, W., Argilés, G., Marabelle, A., Ruíz, M. E., Albanell, J., Calvo, E., Moreno, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx367.036 · Cited by 27
Dengl, S., Sustmann, C., & Brinkmann, U. (2016) · Immunological Reviews · doi:10.1111/imr.12386 · Cited by 26
Khaw, B., Gada, K. S., Patil, V., Panwar, R., Mandapati, S., Hatefi, A., Majewski, S., & Weisenberger, A. G. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2738-2 · Cited by 24
Michalk, I., Feldmann, A., Koristka, S., Arndt, C., Cartellieri, M., Ehninger, A., Ehninger, G., & Bachmann, M. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095517 · Cited by 24
Dovedi, S. J., Mazor, Y., Elder, M. J., Hasani, S., Wang, B., Mosely, S. I. S., Jones, D., Hansen, A. M., Yang, C., Wu, Y., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2776 · Cited by 16
Bispecific antibody complex pre-targeted delivery of polymer–drug conjugates for cancer therapy
Gada, K. S., Patil, V., Panwar, R., Hatefi, A., & Khaw, B. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-011-0055-x · Cited by 15
Kraman, M., Fosh, N., Kmiecik, K., Everett, K. L., Zimarino, C., Faroudi, M., Wydro, M. M., Koers, A., Young, L. L., Gliddon, D., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2719 · Cited by 14
Meric‐Bernstam, F., Beeram, M., Blum, M. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1035 · Cited by 13
Nalivaiko, K., Hofmann‐Apitius, M., Kober, K., Teichweyde, N., Krammer, P. H., Rammensee, H., Große‐Hovest, L., & Jung, G. (2015) · Molecular Therapy · doi:10.1038/mt.2015.209 · Cited by 9
Cited by
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 791
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
“Several different structures have been used for bispecific antibody constructs investigated in oncological clinical trials, as illustrated in a recent review [46].”
BackgroundEmerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
Metadata
- Authors
- Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 201
- Pages
- 103-119
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2940554426
- Cited by
- 292
- References
- 147
- FWCI
- 24.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.